Retrieve available abstracts of 24 articles: HTML format
Single Articles
May 2025
OKAWA S, Tomida S, Kuribayashi T, Nishimura J, et al Colony-stimulating factor-1 receptor inhibitor augments osimertinib-induced
anti-tumor immunity via suppression of macrophages in lung cancer harboring EGFR
mutation.
Mol Cancer Ther. 2025 May 29. doi: 10.1158/1535-7163.MCT-25-0002. PubMedAbstract available
April 2025
DOMINGUEZ-VIGIL IG, Banik K, Baro M, Contessa JN, et al PLK4 inhibition as a strategy to enhance non-small cell lung cancer
radiosensitivity.
Mol Cancer Ther. 2025 Apr 29. doi: 10.1158/1535-7163.MCT-24-0978. PubMedAbstract available
YUAN R, McGeehan A, Zhou S, Cheng C, et al The anti-FRalpha antibody-drug conjugate luveltamab tazevibulin demonstrates efficacy
in non-small cell lung cancer preclinical models and induces immunogenic cell
death.
Mol Cancer Ther. 2025 Apr 28. doi: 10.1158/1535-7163.MCT-24-0649. PubMedAbstract available
March 2025
KOGAI H, Tsukamoto S, Koga M, Miyano M, et al Broad-Spectrum Efficacy of CEACAM6-Targeted Antibody-Drug Conjugate with BET
Protein Degrader in Colorectal, Lung, and Breast Cancer Mouse Models.
Mol Cancer Ther. 2025;24:392-405. PubMedAbstract available
KIM DK, Synn CB, Lee W, Jo HN, et al Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding
Potent Anticancer Effects by Combination with Pembrolizumab.
Mol Cancer Ther. 2025;24:354-369. PubMedAbstract available
January 2025
LU S, Pan X, Volckova E, Shinde A, et al Targeting Monounsaturated Fatty Acid Metabolism for Radiosensitization of KRAS
Mutant 3D Lung Cancer Models.
Mol Cancer Ther. 2025 Jan 21. doi: 10.1158/1535-7163.MCT-24-0213. PubMedAbstract available
December 2024
CALLES A, Calvo E, Santamaria Nunez G, Costanzo F, et al Unveiling the Mechanism of Lurbinectedin's Action and Its Potential in
Combination Therapies in Small Cell Lung Cancer.
Mol Cancer Ther. 2024 Dec 5. doi: 10.1158/1535-7163.MCT-24-0050. PubMedAbstract available
MARTIN-VEGA A, Earnest SA, Augustyn A, Wichaidit C, et al ASCL1 Restrains ERK1/2 to Promote Survival of a Subset of Neuroendocrine Lung
Cancers.
Mol Cancer Ther. 2024;23:1789-1800. PubMedAbstract available
November 2024
OH MS, Dumitras C, Salehi-Rad R, Tran LM, et al Characteristics of a CCL21-gene modified dendritic cell vaccine utilized for a
clinical trial in non-small cell lung cancer.
Mol Cancer Ther. 2024 Nov 19. doi: 10.1158/1535-7163.MCT-24-0435. PubMedAbstract available
October 2024
CINA C, Majeti B, O'Brien Z, Wang L, et al A Novel Lipid Nanoparticle NBF-006 Encapsulating Glutathione S-Transferase P
siRNA for the Treatment of KRAS-driven Non-small Cell Lung Cancer.
Mol Cancer Ther. 2024 Oct 17. doi: 10.1158/1535-7163.MCT-23-0915. PubMedAbstract available
GUO Q, Gao B, Song R, Li W, et al FZ-AD005, a Novel DLL3-Targeted Antibody-Drug Conjugate with Topoisomerase I
Inhibitor, Shows Potent Antitumor Activity in Preclinical Models.
Mol Cancer Ther. 2024;23:1367-1377. PubMedAbstract available
August 2024
DAVE F, Vaghela P, Heath B, Dunster Z, et al SC134-TCB targeting fucosyl-GM1, a T cell engaging antibody with potent
anti-tumour activity in preclinical small-cell lung cancer models.
Mol Cancer Ther. 2024 Aug 26. doi: 10.1158/1535-7163.MCT-24-0187. PubMedAbstract available
RODRIGUEZ BL, Huang J, Gibson L, Fradette JJ, et al Antitumor Activity of a Novel LAIR1 Antagonist in Combination with Anti-PD1 to
Treat Collagen-Rich Solid Tumors.
Mol Cancer Ther. 2024;23:1144-1158. PubMedAbstract available
May 2024
XU Y, Ding K, Peng Z, Ding L, et al Evaluating for Correlations between Specific Metabolites in Patients Receiving
First-Line or Second-Line Immunotherapy for Metastatic or Recurrent NSCLC: An
Exploratory Study Based on Two Cohorts.
Mol Cancer Ther. 2024;23:733-742. PubMedAbstract available
MA W, Wei S, Li Q, Zeng J, et al Simvastatin Overcomes Resistance to Tyrosine Kinase Inhibitors in
Patient-derived, Oncogene-driven Lung Adenocarcinoma Models.
Mol Cancer Ther. 2024;23:700-710. PubMedAbstract available
April 2024
LULLA AR, Akli S, Karakas C, Caruso JA, et al Neutrophil Elastase Remodels Mammary Tumors to Facilitate Lung Metastasis.
Mol Cancer Ther. 2024;23:492-506. PubMedAbstract available
March 2024
MCCRURY M, Swafford K, Shuttleworth SL, Mehdi SH, et al Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of
Oncogenic Pathways in Lymphoma.
Mol Cancer Ther. 2024;23:316-329. PubMedAbstract available
February 2024
HIRAI S, Yamada T, Katayama Y, Ishida M, et al Effects of Combined Therapeutic Targeting of AXL and ATR on Pleural Mesothelioma
Cells.
Mol Cancer Ther. 2024;23:212-222. PubMedAbstract available
January 2024
CHEN N, Tyler LC, Le AT, Welsh EA, et al MIG6 Mediates Adaptive and Acquired Resistance to ALK/ROS1 Fusion Kinase
Inhibition through EGFR Bypass Signaling.
Mol Cancer Ther. 2024;23:92-105. PubMedAbstract available
HILLEN H, Candi A, Vanderhoydonck B, Kowalczyk W, et al A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway
Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma
Models.
Mol Cancer Ther. 2024;23:3-13. PubMedAbstract available
December 2023
GUAN C, Zhang X, Yu L A review of recent advances in the molecular mechanisms underlying brain
metastasis in lung cancer.
Mol Cancer Ther. 2023 Dec 20. doi: 10.1158/1535-7163.MCT-23-0416. PubMedAbstract available
OGIMOTO T, Ozasa H, Tsuji T, Funazo T, et al Combination therapy with EGFR tyrosine kinase inhibitors and TEAD inhibitor
increases tumor suppression effects in EGFR mutation-positive lung cancer.
Mol Cancer Ther. 2023 Dec 6. doi: 10.1158/1535-7163.MCT-23-0371. PubMedAbstract available
KHAN HY, Nagasaka M, Aboukameel A, Alkhalili O, et al Anticancer Efficacy of KRASG12C Inhibitors Is Potentiated by PAK4 Inhibitor
KPT9274 in Preclinical Models of KRASG12C-Mutant Pancreatic and Lung Cancers.
Mol Cancer Ther. 2023;22:1422-1433. PubMedAbstract available
September 2023
WENG W, Meng T, Pu J, Ma L, et al AMT-562, a Novel HER3-targeting Antibody-Drug Conjugate, Demonstrates a Potential
to Broaden Therapeutic Opportunities for HER3-expressing Tumors.
Mol Cancer Ther. 2023;22:1013-1027. PubMedAbstract available